These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21367927)

  • 1. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Rossini M; Adami S
    J Clin Endocrinol Metab; 2011 May; 96(5):1555-9. PubMed ID: 21367927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
    Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin and DKK1 in primary hyperparathyroidism.
    Viapiana O; Fracassi E; Troplini S; Idolazzi L; Rossini M; Adami S; Gatti D
    Calcif Tissue Int; 2013 Apr; 92(4):324-9. PubMed ID: 23430197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin.
    Gatti D; Viapiana O; Adami S; Idolazzi L; Fracassi E; Rossini M
    Bone; 2012 Mar; 50(3):739-42. PubMed ID: 22178539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teriparatide treatment in adult patients with osteogenesis imperfecta type I.
    Gatti D; Rossini M; Viapiana O; Povino MR; Liuzza S; Fracassi E; Idolazzi L; Adami S
    Calcif Tissue Int; 2013 Nov; 93(5):448-52. PubMed ID: 23907723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.
    Dobnig H; Sipos A; Jiang Y; Fahrleitner-Pammer A; Ste-Marie LG; Gallagher JC; Pavo I; Wang J; Eriksen EF
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3970-7. PubMed ID: 15840739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.
    Xu XJ; Shen L; Yang YP; Lu FR; Zhu R; Shuai B; Li CG; Wu MX
    Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Dickkopf 1 levels in sclerostin deficiency.
    van Lierop AH; Moester MJ; Hamdy NA; Papapoulos SE
    J Clin Endocrinol Metab; 2014 Feb; 99(2):E252-6. PubMed ID: 24302746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
    Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.
    Glover SJ; Eastell R; McCloskey EV; Rogers A; Garnero P; Lowery J; Belleli R; Wright TM; John MR
    Bone; 2009 Dec; 45(6):1053-8. PubMed ID: 19679211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study.
    Liakou CG; Mastorakos G; Makris K; Fatouros IG; Avloniti A; Marketos H; Antoniou JD; Galanos A; Dontas I; Rizos D; Tournis S
    Endocrine; 2016 Nov; 54(2):543-551. PubMed ID: 27601021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study.
    Ardawi MS; Rouzi AA; Al-Sibiani SA; Al-Senani NS; Qari MH; Mousa SA
    J Bone Miner Res; 2012 Dec; 27(12):2592-602. PubMed ID: 22836717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation.
    Sridharan M; Cheung J; Moore AE; Frost ML; Fraser WD; Fogelman I; Hampson G
    Calcif Tissue Int; 2010 Nov; 87(5):398-405. PubMed ID: 20838781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients.
    Wang N; Xue P; Wu X; Ma J; Wang Y; Li Y
    Endocr Res; 2018 Feb; 43(1):29-38. PubMed ID: 28972408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone.
    Idolazzi L; Fassio A; Tripi G; Braga V; Viapiana O; Adami G; Rossini M; Gatti D
    Clin Rheumatol; 2017 Apr; 36(4):925-928. PubMed ID: 28054306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.